COPENHAGEN, Denmark, Sept. 29, 2026 -- Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announced the successful close of...
BrainCells Gets $8M In First Part Of Committed $17.7M Series A
News | 07. 15. 2005
BrainCells
BrainCells Inc., a neuroscience-focused drug discovery and development company targeting therapies for depression, related neuropsychiatric disorders and other central nervous system diseases, has closed on commitments of $17.7 million for its Series A round.
